Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics announces pricing of private placement

  • Read more about Bone Therapeutics announces pricing of private placement

Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent

  • Read more about Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent

Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants

  • Read more about Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants

Bone Therapeutics Provides Third Quarter 2020 Business Update

  • Read more about Bone Therapeutics Provides Third Quarter 2020 Business Update

Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

  • Read more about Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

Transparency notification received from S.R.I.W. SA and Sofipôle SA

  • Read more about Transparency notification received from S.R.I.W. SA and Sofipôle SA

Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)

Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

  • Read more about Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

  • Read more about Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa

  • Read more about Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions